Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06242470 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06242470 · ClinicalTrials.gov record · last posted 2026-08-11

A Study of MGC026 in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started2024-03-06
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.

Amendment record 15 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 15 times since 2024-02-01; most recent amendment 2026-02-03. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-03-13
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06242470
Lead Sponsor MacroGenics
Conditions Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma +14 more
Enrollment 250 participants
Start Date 2024-03-06
Primary Completion 2028-05 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-11